MMWR. Morbidity and mortality weekly report最新文献_第4页

QuickStats: Health Center* Visit Rates,^† by Adults Aged ≥18 Years with Mental Health Disorder,^§ Substance Use Disorder, or Both, by Sex - United States, 2023. QuickStats：健康中心*访问率，†按年龄≥18岁患有精神健康障碍，§物质使用障碍或两者兼而有之的成年人，按性别分列-美国，2023。

IF 25.4 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2025-01-09 DOI: 10.15585/mmwr.mm7401a4

引用次数: 0

Tularemia - United States, 2011-2022. Tularemia -美国，2011-2022。

IF 25.4 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2025-01-02 DOI: 10.15585/mmwr.mm735152a1

Shannan N Rich, Alison F Hinckley, Austin Earley, Jeannine M Petersen, Paul S Mead, Kiersten J Kugeler

{"title":"Tularemia - United States, 2011-2022.","authors":"Shannan N Rich, Alison F Hinckley, Austin Earley, Jeannine M Petersen, Paul S Mead, Kiersten J Kugeler","doi":"10.15585/mmwr.mm735152a1","DOIUrl":"10.15585/mmwr.mm735152a1","url":null,"abstract":"Tularemia is a rare nationally notifiable zoonosis, caused by the tier-1 select agent Francisella tularensis, that has been reported from all U.S. states except Hawaii. Clinical manifestations typically include fever and localized symptoms that vary by route of infection. The case fatality rate of tularemia is typically <2% but can be higher depending on clinical manifestation and infecting strain. Tularemia is treatable with antibiotics. During 2011-2022, a total of 47 states reported 2,462 tularemia cases, but four central states (Arkansas, Kansas, Missouri, and Oklahoma) accounted for 50% of all reported cases. Incidence was highest among children aged 5-9 years (0.083 per 100,000 population) and adult males aged 65-84 years (range = 0.133-0.161). Incidence among American Indian or Alaska Native persons (0.260) was approximately five times that among White persons (0.057). The average annual incidence of tularemia in the United States during 2011-2022 (0.064) was 56% higher than that reported during 2001-2010 (0.041), largely resulting from increased reporting of probable cases. These findings might reflect an actual increase in human infection or improved case detection amid changes in commercially available laboratory tests during this period. Reducing tularemia incidence will require tailored prevention education; mitigating morbidity and mortality will require health care provider education, particularly among providers serving tribal populations, regarding early and accurate diagnosis and treatment.","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"73 5152","pages":"1152-1156"},"PeriodicalIF":25.4,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142907269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

QuickStats: Mental Health Treatment Trends* Among Adults Aged ≥18 Years, by Age Group - United States, 2019-2023^†. QuickStats: 2019-2023年美国年龄≥18岁成年人心理健康治疗趋势*

IF 25.4 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2024-12-19 DOI: 10.15585/mmwr.mm7350a5

引用次数: 0

Notes from the Field: Long COVID and Significant Long COVID-Associated Activity Limitation Among Adults, by Jurisdiction - United States, 2023. 现场说明：按司法管辖区划分的成年人长期COVID和重大长期COVID相关活动限制-美国，2023年。

IF 25.4 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2024-12-19 DOI: 10.15585/mmwr.mm7350a2

Nicole D Ford, Abraham Agedew, Alexandra F Dalton, Caroline Pratt, Cria O Gregory, Sharon Saydah

引用次数: 0

Notes from the Field: Geo-Temporal Trends in Fentanyl Administration Routes Among Adults Reporting Use of Illegally Manufactured Fentanyl When Assessed for Substance-Use Treatment - 14 U.S. States, 2017-2023. 来自该领域的注释：当评估物质使用治疗时，报告使用非法制造芬太尼的成年人中芬太尼给药途径的地理时间趋势-美国14个州，2017-2023。

IF 25.4 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2024-12-19 DOI: 10.15585/mmwr.mm7350a4

Yijie Chen, Xinyi Jiang, R Matthew Gladden, Nisha Nataraj, Gery P Guy, Deborah Dowell

引用次数: 0

Notes from the Field: School-Based Surveillance of Mycoplasma pneumoniae Trends and Impact on School Attendance by Students and Staff Members - Missouri, Fall 2024. 现场记录：以学校为基础的肺炎支原体趋势监测和学生和工作人员对学校出勤率的影响-密苏里州，2024年秋季。

IF 25.4 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2024-12-19 DOI: 10.15585/mmwr.mm7350a3

Olivia M Almendares, Brittney Fritschmann, Rangaraj Selvarangan, Brian R Lee, Chris Edens, Maureen Diaz, Brett Whitaker, Shannon Tilsworth, Janelle Porter, Nibha Sagar, Jennifer E Schuster, Jennifer L Goldman, Hannah L Kirking

引用次数: 0

Surveillance of Human Adenovirus Types and the Impact of the COVID-19 Pandemic on Reporting - United States, 2017-2023. 人类腺病毒类型监测和 COVID-19 大流行对报告的影响 - 美国，2017-2023 年。

IF 25.4 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2024-12-19 DOI: 10.15585/mmwr.mm7350a1

Fatima Abdirizak, Amber K Winn, Rishika Parikh, Heather M Scobie, Xiaoyan Lu, Everardo Vega, Olivia Almendares, Hannah L Kirking, Erica Billig Rose, Benjamin J Silk

{"title":"Surveillance of Human Adenovirus Types and the Impact of the COVID-19 Pandemic on Reporting - United States, 2017-2023.","authors":"Fatima Abdirizak, Amber K Winn, Rishika Parikh, Heather M Scobie, Xiaoyan Lu, Everardo Vega, Olivia Almendares, Hannah L Kirking, Erica Billig Rose, Benjamin J Silk","doi":"10.15585/mmwr.mm7350a1","DOIUrl":"10.15585/mmwr.mm7350a1","url":null,"abstract":"Human adenoviruses (HAdVs) are typically associated with mild respiratory illnesses, although severe disease and outbreaks in congregate settings occur. The National Adenovirus Type Reporting System (NATRS) is a passive, laboratory-based surveillance system that monitors trends in circulation of HAdV types in the United States. This report summarizes the distribution of HAdV types reported to NATRS during 2017-2023. During this 7-year period, 2,241 HAdV specimens with typing results were reported to NATRS. The number of specimens with HAdV typing results reported varied annually during 2017-2019 (range = 389-562) and declined during 2020-2023 (range = 58-356). During 2017-2023, six HAdV types (1-4, 7, and 14) accounted for 88.3% of typed specimens reported; 17.0% of specimens were identified as outbreak-related. An increase in type 41 reporting was associated with a hepatitis cluster during 2021-2022. Reporting to NATRS has declined since the COVID-19 pandemic, despite continued HAdV circulation reported through passive laboratory surveillance to the National Respiratory and Enteric Virus Surveillance System. Enhanced participation in NATRS is needed to improve monitoring of circulating HAdV types.","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"73 50","pages":"1136-1141"},"PeriodicalIF":25.4,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11658400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progress Toward Poliomyelitis Eradication - Afghanistan, January 2023-September 2024. 消灭脊髓灰质炎的进展——阿富汗，2023年1月至2024年9月。

IF 25.4 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2024-12-12 DOI: 10.15585/mmwr.mm7349a4

Colleen Mone Hardy, Mandeep Rathee, Sumangala Chaudhury, Mufti Zubair Wadood, Fazal Ather, Elizabeth Henderson, Maureen Martinez

{"title":"Progress Toward Poliomyelitis Eradication - Afghanistan, January 2023-September 2024.","authors":"Colleen Mone Hardy, Mandeep Rathee, Sumangala Chaudhury, Mufti Zubair Wadood, Fazal Ather, Elizabeth Henderson, Maureen Martinez","doi":"10.15585/mmwr.mm7349a4","DOIUrl":"10.15585/mmwr.mm7349a4","url":null,"abstract":"Since the Global Polio Eradication Initiative began in 1988, wild poliovirus (WPV) types 2 and 3 have been eradicated, and annual polio case numbers have decreased by >99.9%. WPV type 1 (WPV1) transmission remains endemic in Afghanistan and Pakistan, two countries that share a 1,600-mile (2,600-km) border. This report describes immunization and surveillance activities and progress toward polio eradication in Afghanistan during January 2023-September 2024. As of November 1, Afghanistan reported 23 WPV1 cases in 2024, with onset during January-September 30, 2024. During the 3 previous years, 12 WPV1 cases were reported, including six during 2023. In August 2021, the Taliban took control nationwide and allowed increased geographic access for poliovirus vaccination campaigns. Multiple challenges have affected polio eradication activities in Afghanistan, including mandated repatriation of approximately 1 million Afghans by Pakistan beginning in late 2023, the ongoing humanitarian crisis that limits international agency effectiveness, polio program constraints imposed by authorities, and increased restrictions on female participation in vaccination activities. House-to-house vaccination coverage reached 90%-98% of children during June-July 2024. Beginning in 2021, authorities had progressively lifted restrictions on house-to-house campaigns, but abruptly reverted to national restrictions in September 2024. Both nationwide house-to-house activities and strengthening of the routine childhood immunization program would help ensure that every vulnerable child is vaccinated and provide a pathway to polio eradication in Afghanistan.","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"73 49","pages":"1129-1134"},"PeriodicalIF":25.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11637418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142818681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiology of Dengue - Puerto Rico, 2010-2024. 2010-2024年波多黎各登革热流行病学。

IF 25.4 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2024-12-12 DOI: 10.15585/mmwr.mm7349a1

Dania M Rodriguez, Zachary J Madewell, Jomil M Torres, Aidsa Rivera, Joshua M Wong, Gilberto A Santiago, Vanessa Rivera-Amill, Gabriela Paz-Bailey, Melissa Marzan-Rodriguez, Laura E Adams

{"title":"Epidemiology of Dengue - Puerto Rico, 2010-2024.","authors":"Dania M Rodriguez, Zachary J Madewell, Jomil M Torres, Aidsa Rivera, Joshua M Wong, Gilberto A Santiago, Vanessa Rivera-Amill, Gabriela Paz-Bailey, Melissa Marzan-Rodriguez, Laura E Adams","doi":"10.15585/mmwr.mm7349a1","DOIUrl":"10.15585/mmwr.mm7349a1","url":null,"abstract":"Dengue is a mosquitoborne viral illness that can cause acute febrile illness, severe disease, or death. Worldwide, the number of dengue cases is increasing. During the last dengue outbreaks in Puerto Rico throughout 2010-2013, dengue virus (DENV) serotype 1 (DENV-1) predominated, and the largest proportion of cases occurred among adolescents and young adults aged 10-19 years. Dengue case data from January 1, 2010-November 4, 2024, were obtained from the Puerto Rico Department of Health. Bivariate analyses were conducted to evaluate the distribution of cases by patient age, DENV serotype, and hospitalization status during three periods: 2010-2019, 2020-2022, and 2023-2024. During 2023-2024, the median age of dengue cases increased to 26 years (95% CI = 25-27 years) compared with that during 2020-2022 (17 years; 95% CI = 17-18 years) and 2010-2019 (19 years; 95% CI = 19-19 years). After >10 years of DENV-1 predominance, the proportions of DENV serotypes 2 (DENV-2) and 3 (DENV-3) increased significantly during 2023-2024, with DENV-3 replacing DENV-1 as the predominant serotype. In addition, the proportion of dengue patients who were hospitalized increased from 35.7% (2010-2019) to 53.5% (2023-2024). The current dengue outbreak in Puerto Rico marks a shift in serotype predominance to DENV-3 and increasing percentages of cases in older age groups (61.7% in adults aged ≥20 years), although a high proportion of cases still occur among adolescents aged 10-19 years (29.5%). The current dengue outbreak also has a higher rate of hospitalizations than those in previous years. Understanding the changing epidemiology of dengue is crucial to guiding public health strategies for dengue control, including clinical management, surveillance and health care system resilience, and public outreach and education.","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"73 49","pages":"1112-1117"},"PeriodicalIF":25.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11637419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142818673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Dosing Interval and Schedule for the Bexsero MenB-4C Vaccine: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, October 2024. Bexsero MenB-4C 疫苗的新给药间隔和时间表：免疫实践咨询委员会的最新建议 - 美国，2024 年 10 月。

IF 25.4 1区医学

MMWR. Morbidity and mortality weekly report Pub Date : 2024-12-12 DOI: 10.15585/mmwr.mm7349a3

Sarah Schillie, Jamie Loehr, Wilbur H Chen, Charlotte A Moser, Gabrielle Cooper, Cheryl Isenhour, Lucy A McNamara

{"title":"New Dosing Interval and Schedule for the Bexsero MenB-4C Vaccine: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, October 2024.","authors":"Sarah Schillie, Jamie Loehr, Wilbur H Chen, Charlotte A Moser, Gabrielle Cooper, Cheryl Isenhour, Lucy A McNamara","doi":"10.15585/mmwr.mm7349a3","DOIUrl":"10.15585/mmwr.mm7349a3","url":null,"abstract":"Two meningococcal serogroup B vaccines are licensed for use in the United States. In August 2024, the Food and Drug Administration (FDA) changed the label for the meningococcal serogroup B MenB-4C vaccine (Bexsero) from a 2-dose schedule (intervals of 0 and ≥1 month) to a 2-dose schedule (0 and 6 months) and added a 3-dose schedule (0, 1-2, and 6 months), based on new immunogenicity data. On October 24, 2024, the Advisory Committee on Immunization Practices (ACIP) voted to update its recommendations for the MenB-4C dosing interval and schedule to align with the new FDA label. ACIP recommends extending the interval for the 2-dose series of MenB-4C from 0 and ≥1 month to 0 and 6 months for healthy adolescents and young adults aged 16-23 years based on shared clinical decision-making and has added a recommendation for a 3-dose series with doses administered at 0, 1-2, and 6 months for persons aged ≥10 years at increased risk. The updated ACIP recommendations for MenB-4C align with existing ACIP recommendations for the other FDA-licensed meningococcal serogroup B vaccine, MenB-FHbp (Trumenba).","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"73 49","pages":"1124-1128"},"PeriodicalIF":25.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11637420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142818678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0